Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
INSMthis companyInsmed Incorporated	$114.81	-27.15×	50.31×	61.31×	-31.96×	-253.3%	79.4%	-194.0%	-210.5%	-172.8%	-64.8%	-2.6%	1.04×	-0.22×	-14.04×	3.83×	0.0%	4	6.45	1	D+
AVLNAvalyn Pharma Inc. Common Stock	$29.41	-14.46×	-5.17×	0×	-12.96×	-95.6%	0.0%	0.0%	0.0%	35.7%	-67.5%	-6.6%	-0.01×	0.56×	0×	10.19×	0.0%	—	—	2	C
LQDALiquidia Corporation	$47.62	-43.11×	66.33×	18.75×	-68.84×	-288.6%	91.6%	-32.5%	-43.5%	-154.0%	-20.5%	-1.3%	4.42×	-0.17×	-2.13×	1.4×	0.0%	6	8.09	3	B-
PULMPulmatrix, Inc.	$1.39	-1.58×	2.14×	0×	-0.79×	-24.7%	0.0%	0.0%	0.0%	-135.5%	-135.7%	-66.7%	0×	0.79×	0×	12.55×	0.0%	1	-130.04	2	C
UTHRUnited Therapeutics Corporation	$569.92	16.17×	3.04×	6.78×	11.03×	23.4%	87.9%	47.7%	41.9%	18.8%	16.1%	4.8%	0.01×	-0.84×	77.81×	6.6×	0.0%	6	22.22	4	A-
Peer median	—	-8.02×	2.59×	3.39×	-6.87×	-60.1%	44.0%	0.0%	0.0%	-58.3%	-44.0%	-4.0%	0×	0.19×	0×	8.4×	0.0%	6	8.09	3	—